A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cell

• Publication date

  2010-05-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.cell.2010.04.020PMID 20478252PMCID PMC2882693
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rhythmic gene expression in somite formation and neural development

  2009cited by this paper
• Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis

  2009cited by this paper
• Active Notch1 confers a transformed phenotype to primary human melanocytes.

  2009cited by this paper
• Is tumor growth sustained by rare cancer stem cells or dominant clones?

  2008influential reference
• Identification of cells initiating human melanomas

  2008influential reference
• Efficient tumour formation by single human melanoma cells

  2008influential reference
• The Histone Demethylase KDM5b/JARID1b Plays a Role in Cell Fate Decisions by Blocking Terminal Differentiation

  2008cited by this paper
• The epithelial-mesenchymal transition generates cells with properties of stem cells.

  2008influential reference
• Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics

  2008cited by this paper
• Dynamic Notch signaling in neural progenitor cells and a revised view of lateral inhibition

  2008cited by this paper
• Efficient tumor formation by single human melanoma cells

  2008cited by this paper
• Melanoma stem cells: the dark seed of melanoma.

  2008cited by this paper
• Tumor Growth Need Not Be Driven by Rare Cancer Stem Cells

  2007cited by this paper
• A chromatin landmark and transcription initiation at most promoters in human cells.

  2007cited by this paper
• RBP2‐H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells

  2007influential reference
• RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3.

  2007cited by this paper
• The retinoblastoma binding protein RBP2 is an H3K4 demethylase.

  2007cited by this paper
• Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential.

  2007influential reference
• MLL translocations, histone modifications and leukaemia stem-cell development

  2007cited by this paper
• Functional Analysis of the Transcription Repressor PLU-1/JARID1B

  2007cited by this paper
• Chemotherapy for metastatic melanoma

  2007cited by this paper
• PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation.

  2007cited by this paper
• The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases.

  2007cited by this paper
• Notch signaling via Hes1 transcription factor maintains survival of melanoblasts and melanocyte stem cells

  2006cited by this paper
• Rb family proteins as modulators of gene expression and new aspects regarding the interaction with chromatin remodeling enzymes

  2006influential reference
• Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

  2006influential reference
• Neural crest–derived cells with stem cell features can be traced back to multiple lineages in the adult skin

  2006cited by this paper
• Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression.

  2006cited by this paper
• Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals tumor-suppressive functions in highly metastatic melanoma cells.

  2006influential reference
• Melanoma, a tumor based on a mutant stem cell?

  2006cited by this paper
• Roles of jumonji and jumonji family genes in chromatin regulation and development

  2006cited by this paper
• Faculty Opinions recommendation of Notch signaling via Hes1 transcription factor maintains survival of melanoblasts and melanocyte stem cells.

  2006cited by this paper
• Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas

  2005influential reference
• Why Therapeutic Response May Not Prolong the Life of a Cancer Patient: Selection for Oncogenic Resistance

  2005cited by this paper
• A tumorigenic subpopulation with stem cell properties in melanomas.

  2005influential reference
• Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression.

  2005cited by this paper
• Nomenclature of the ARID family of DNA-binding proteins.

  2005cited by this paper
• A short region of the promoter of the breast cancer associated PLU-1 gene can regulate transcription in vitro and in vivo.

  2004cited by this paper
• Isolation of cancer stem cells from adult glioblastoma multiforme

  2004cited by this paper
• Identification of human brain tumour initiating cells

  2004cited by this paper
• In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells.

  2003cited by this paper
• Human PLU-1 Has Transcriptional Repression Properties and Interacts with the Developmental Transcription Factors BF-1 and PAX9*

  2003influential reference
• Identification of a cancer stem cell in human brain tumors.

  2003cited by this paper
• PLU‐1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: A new cancer/testis antigen?

  2002cited by this paper
• Stem cells, cancer, and cancer stem cells

  2001influential reference
• Deficiency of a novel retinoblastoma binding protein 2-homolog is a consistent feature of sporadic human melanoma skin cancer.

  1999cited by this paper
• A Novel Gene (PLU-1) Containing Highly Conserved Putative DNA/Chromatin Binding Motifs Is Specifically Up-regulated in Breast Cancer*

  1999cited by this paper
• Melanoma cell lines from different stages of progression and their biological and molecular analyses

  1997cited by this paper
• Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

  1997cited by this paper
• Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo

  1996cited by this paper

• Targeting persister cells: proactively overcoming therapy resistance in aggressive B cell lymphomas.

  2026cites this paper
• The role of KDM5B in creating synthetic vulnerabilities in combination with radiotherapy in melanoma cells.

  2026cites this paper
• Neural crest gene regulatory networks as drivers of development, diversification and disease.

  2026cites this paper
• Cancer stem cells in focus: Deciphering the dynamic functional landscape of stemness in cancer.

  2025cites this paper
• Imaging Clusters of Pediatric Low-Grade Glioma Are Associated with Distinct Molecular Characteristics

  2025cites this paper
• Roles of KDM5 demethylases in therapeutic resistance of cancers

  2025cites this paper
• Transformer-based modeling of Clonal Selection and Expression Dynamics reveals resistance mechanisms in breast cancer

  2025cites this paper
• Androgen Deprivation-Induced TET2 Activation Fuels Prostate Cancer Progression via Epigenetic Priming and Slow-Cycling Cancer Cells

  2025cites this paper
• Identification of a shared persistence program in triple-negative breast cancer across treatments and patients

  2025cites this paper
• A multi-step immune-competent genetic mouse model reveals phenotypic plasticity in uveal melanoma

  2025cites this paper
• Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review

  2025cites this paper
• Canonical and Non‐Canonical Functions of Histone H3K4 Methylation Modifiers in Cancer

  2025cites this paper
• Super-enhancer PPP1R15B/EIF2A axis characterizes aggressive drug-tolerant persister cells in Glioblastoma.

  2025cites this paper
• Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells.

  2025cites this paper
• Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment

  2025cites this paper
• GPNMB marks a quiescent cell population in melanoma and promotes metastasis formation

  2025influential citation
• Optimizing chemoradiotherapy for malignant gliomas: a validated mathematical approach

  2025cites this paper
• Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticity

  2025cites this paper
• Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models

  2025cites this paper
• Comprehensive Review of Methods for Cancer Stem Cell Identification and Characterization

  2025cites this paper
• Towards understanding cancer dormancy over strategic hitching up mechanisms to technologies

  2025cites this paper
• Identification of genomic features that uniquely impact estrogen receptor alpha binding and its effects on gene expression in endometrial cancer

  2025cites this paper
• Confronting Melanoma Radioresistance: Mechanisms and Therapeutic Strategies

  2025cites this paper
• Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanoma

  2025cites this paper
• MITF, TFEB, and TFE3 drive distinct adaptive gene expression programs and immune infiltration in melanoma

  2025cites this paper
• Comprehensive Analysis of BRCA1/2 mutations, "BRCAness" and PARP inhibitors in Melanoma.

  2025cites this paper
• Targeting Cancer Drug-Tolerant Persister Cells in Minimal Residual Disease

  2025cites this paper
• Tumors and their microenvironments: Learning from pediatric brain pathologies

  2025cites this paper
• Drug-Resistant Cholangiocarcinoma Cell Lines for Therapeutic Evaluation of Novel Drugs

  2025cites this paper
• Human stem cell models for group 3 medulloblastoma uncover JARID1B as a regulator of the chromatin landscape

  2025cites this paper
• A methyl-to-acetyl switch in H3K27 drives metabolic reprogramming and resistance to BRAFV600E inhibition in melanoma

  2025cites this paper
• MCSP+ metastasis founder cells activate immunosuppression early in human melanoma metastatic colonization

  2025cites this paper
• MAPK and mTORC1 signaling converge on Cyclin D to enable cell-cycle re-entry in melanoma persister cells

  2025cites this paper
• A memory-driven reinforcement learning model of phenotypic adaptation for anticipating therapeutic resistance in prostate cancer

  2025cites this paper
• 20 years of histone lysine demethylases: From discovery to the clinic and beyond.

  2025cites this paper
• Diagnosis and therapeutic targeting of quiescent cancer cells: road to conquer cancer recurrence

  2025cites this paper
• Prospective Isolation According to Melanin Pigment Content of Melanoma Cells With Heterogeneous Potentials for Disease Propagation

  2025cites this paper
• Epigenetic regulation of cancer stemness

  2025cites this paper
• The emerging roles of histone demethylases in cancers

  2024cites this paper
• The population context is a driver of the heterogeneous response of epithelial cells to interferons

  2024cites this paper
• Spatiotemporal profiling defines persistence and resistance dynamics during targeted treatment of melanoma

  2024influential citation
• Optimal dosing of anti-cancer treatment under drug-induced plasticity

  2024cites this paper
• Spatiotemporal Profiling Defines Persistence and Resistance Dynamics During Targeted Treatment of Melanoma.

  2024cites this paper
• DOT1L Mediates Stem Cell Maintenance and Represents a Therapeutic Vulnerability in Cancer

  2024cites this paper
• Dormancy and awakening of cancer cells: the extracellular vesicle-mediated cross-talk between Dr. Jekill and Mr. Hyde

  2024cites this paper
• AP-1 Mediates Cellular Adaptation and Memory Formation During Therapy Resistance

  2024cites this paper
• A Multi-Omics Prognostic Model Capturing Tumor Stemness and the Immune Microenvironment in Clear Cell Renal Cell Carcinoma

  2024cites this paper
• MITF, TFEB and TFE3 drive distinct adaptive gene expression programs and immune infiltration in melanoma

  2024cites this paper
• The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations

  2024cites this paper
• Three-dimensional imaging of upper tract urothelial carcinoma improves diagnostic yield and accuracy

  2024cites this paper
• Epithelial–Mesenchymal Plasticity and Epigenetic Heterogeneity in Cancer

  2024cites this paper
• NOTCH3 promotes malignant progression of bladder cancer by directly regulating SPP1 and activating PI3K/AKT pathway

  2024cites this paper
• Epigenetic modulators provide a path to understanding disease and therapeutic opportunity

  2024cites this paper
• Integrated analysis of colorectal cancer metastasis identifies characteristics of tumor cell during metastasis

  2024cites this paper
• Functional consequences of a p53-MDM2-p21 incoherent feedforward loop

  2024cites this paper
• Spatial transcriptomics reveals influence of microenvironment on intrinsic fates in melanoma therapy resistance

  2024cites this paper
• Unveiling cancer dormancy: intrinsic mechanisms and extrinsic forces.

  2024cites this paper
• CD146, a therapeutic target involved in cell plasticity

  2024influential citation
• MiR-29 and MiR-140 regulate TRAIL-induced drug tolerance in lung cancer

  2024cites this paper
• Senescence Promotes the Recovery of Stemness among Cancer Cells via Reprograming

  2024cites this paper
• Mathematical modeling and dynamic analysis for cancer resistance incorporating persister cells

  2024cites this paper
• Mechanistic QSAR modeling derived virtual screening, drug repurposing, ADMET and in-vitro evaluation to identify anticancer lead as lysine-specific demethylase 5a inhibitor

  2024cites this paper
• Discovery of an efficacious KDM5B PROTAC degrader GT-653 up-regulating IFN response genes in prostate cancer.

  2024cites this paper
• Determinants of resistance and response to melanoma therapy

  2024cites this paper
• Targeted Liposomes Sensitize Plastic Melanoma to Ferroptosis via Senescence Induction and Coenzyme Depletion.

  2024cites this paper
• Clonal differences underlie variable responses to sequential and prolonged treatment.

  2024cites this paper
• 15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

  2024cites this paper
• Pharmacological Agents Targeting Drug-Tolerant Persister Cells in Cancer.

  2024cites this paper
• Artesunate attenuates the tumorigenesis of choroidal melanoma via inhibiting EFNA3 through Stat3/Akt signaling pathway

  2024cites this paper
• Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance

  2024cites this paper
• Mouse Tail‐Skin Dissociation and Preparation of Live Single‐Cell Suspension for Downstream Analysis of Melanocytes

  2024cites this paper
• Transcription factor activating enhancer-binding protein 2ε (AP2ε) modulates phenotypic plasticity and progression of malignant melanoma

  2024cites this paper
• KR158 Spheres Harboring Slow-Cycling Cells Recapitulate High-Grade Glioma Features in an Immunocompetent System

  2024cites this paper
• Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies

  2024cites this paper
• ER stress and the unfolded protein response in gastrointestinal stem cells and carcinogenesis.

  2024cites this paper
• KDM5B predicts temozolomide-resistant subclones in glioblastoma

  2023cites this paper
• Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy

  2023cites this paper
• Sniping Cancer Stem Cells with Nanomaterials.

  2023cites this paper
• Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies

  2023cites this paper
• Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cells.

  2023cites this paper
• KDM5 Lysine Demethylases in Pathogenesis, from Basic Science Discovery to the Clinic.

  2023cites this paper
• The epigenome and the many facets of cancer drug tolerance.

  2023cites this paper
• Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer

  2023cites this paper
• Putative Cancer Stem Cell Markers are Frequently Expressed by Melanoma Cells in Vitro and in Situ but are also Present in Benign Differentiated Cells.

  2023cites this paper
• Cancer metastasis: Molecular mechanisms and clinical perspectives.

  2023cites this paper
• Mitochondria in Cancer Stem Cells: From an Innocent Bystander to a Central Player in Therapy Resistance

  2023cites this paper
• Drug-tolerant persister cells in cancer: the cutting edges and future directions

  2023cites this paper
• CCDC50 promotes tumor growth through regulation of lysosome homeostasis

  2023cites this paper
• Lysine demethylase 5B (KDM5B): A key regulator of cancer drug resistance

  2023cites this paper
• IN VIVO ISOLATION OF A QUIESCENT MELANOMA POPULATION WITH INVASIVE PROPERTIES UNVEILS A TRANSCRIPTIONAL REPROGRAMMING DRIVEN BY THE TUMOR NICHE

  2023cites this paper
• H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferase

  2023cites this paper
• DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype.

  2023cites this paper
• Vienna Cancer Stem Cell Club (VCSCC): 20 year jubilee and future perspectives

  2023cites this paper
• PLX4032 resistance of patient-derived melanoma cells: crucial role of oxidative metabolism

  2023cites this paper
• Dysregulated Signalling Pathways Driving Anticancer Drug Resistance

  2023cites this paper
• Cancer cell plasticity during tumor progression, metastasis and response to therapy

  2023cites this paper
• Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells

  2023cites this paper
• Statistical inference of the rates of cell proliferation and phenotypic switching in cancer.

  2023cites this paper
• N6-methyladenosine modification of FZR1 mRNA promotes gemcitabine resistance in pancreatic cancer.

  2023cites this paper
• Pirin is a prognostic marker of human melanoma that dampens the proliferation of malignant cells by downregulating JARID1B/KDM5B expression

  2023cites this paper